| Literature DB >> 30060570 |
Yen-Chun Koh1, Guliang Yang2, Ching-Shu Lai3, Monthana Weerawatanakorn4, Min-Hsiung Pan5,6,7,8.
Abstract
Macrophages can polarize into two different states (M1 and M2), which play contrasting roles during pathogenesis or tissue damage. M1 polarized macrophages produce pro-inflammatory cytokines and mediators resulting in inflammation, while M2 macrophages have an anti-inflammatory effect. Secretion of appropriate cytokines and chemokines from macrophages can lead to the modification of the microenvironment for bridging innate and adaptive immune responses. Increasing evidence suggests that polarized macrophages are pivotal for disease progression, and the regulation of macrophage polarization may provide a new approach in therapeutic treatment of inflammation-related diseases, including cancer, obesity and metabolic diseases, fibrosis in organs, brain damage and neuron injuries, and colorectal disease. Polarized macrophages affect the microenvironment by secreting cytokines and chemokines while cytokines or mediators that are produced by resident cells or tissues may also influence macrophages behavior. The interplay of macrophages and other cells can affect disease progression, and therefore, understanding the activation of macrophages and the interaction between polarized macrophages and disease progression is imperative prior to taking therapeutic or preventive actions. Manipulation of macrophages can be an entry point for disease improvement, but the mechanism and potential must be understood. In this review, some advanced studies regarding the role of macrophages in different diseases, potential mechanisms involved, and intervention of drugs or phytochemicals, which are effective on macrophage polarization, will be discussed.Entities:
Keywords: M1/M2 macrophage; chemoprevention; inflammation; phytochemicals
Mesh:
Substances:
Year: 2018 PMID: 30060570 PMCID: PMC6121620 DOI: 10.3390/ijms19082208
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Inducers and samples intervened in isolated macrophages and/or macrophage cell lines polarization with genes expressed, cytokines/chemokines produced, and surface markers being observed and used as indicators of polarized macrophages of different states in some recent studies. (Samples intervened were underlined to differentiate with inducers.)
| Isolated Macrophages and/or Macrophage Cell Lines | Inducers/ | Gene Expressed | Cytokines/Chemokines | Surface Markers | References |
|---|---|---|---|---|---|
| RAW264.7 | LPS + IFNγ | IL-1β, IL-6, TNF-α (M1) | - | [ | |
| RAW264.7 | LPS (200 ng/mL) | - | TNF-α, IL-6, GM-CSF, IL-1α, G-CSF (M1), COX-2 (M1) | CD86 (M1) CD206 (M2) | [ |
| RAW264.7 | LPS (100 ng/mL) + IFNγ (2.5 ng/mL) | - | CD86 (M1) | [ | |
| CD14+ isolated human peripheral blood monocytes | M-CSF/IFNγ (100 ng/mL) + M-CSF LPS (100 ng/mL) | TNFα, IL-6 (M1) IL-10 (M2) | - | [ | |
| Peritoneal macrophage | LPS (20 ng/mL) + IFNγ (1 µg/mL)/IL-4 (20 ng/mL) | - | - | [ | |
| RAW264.7 | IL-4/IL13 (10 ng/mL) + | STAT6 (M2) | CD206 (M2) | [ | |
| Peritoneal macrophage | LPS (100 ng/mL) + IFNγ (10 ng/mL)/IL-4 (200 ng/mL) | - | - | [ | |
| RAW264.7 ANA-1 THP-1 Murine peritoneal cells | LPS (500 ng/ mL)/IL-4 (10 ng/mL) + | MHCII, CCR7, TNF-α, (M1) | CD80 (M1)- | [ | |
| RAW264.7 Bone marrow derived macrophage | LPS (100 ng/mL) + IL-4 (10 ng/mL)/10 ng/mL + | - | CD11c (M1) CD206 (M2) | [ | |
| Murine peritoneal Macrophages RAW264.7 | LPS/IL-4 + | TNF-α, CCL2, IL-1β, IL-6, IL-12, CCR7, MHCII (M1) IL-10, Arg-1, MGL1/2 (M2) | CD80 (M1) CD206 (M2) | [ | |
| RAW264.7 | IL-4,IL-13, MMR and Arg-1 (M2) | - | [ | ||
| Murine peritoneal macrophages | LPS (100 ng/mL) | - | iNOS, COX-2 (M1) | - | [ |
| RAW264.7 | Tim-3 overexpressing | - | - | [ | |
| Mouse peritoneal macrophages | LPS (10-100 ng/mL) + | - | - | [ | |
| RAW264.7 | LPS/Adipocytes-conditioned medium + | TNF-α, IL-1β, IL-6, MCP1, CCR7 (M1) | CD11c, CD86 (M1) CD206, CD163 (M2) | [ | |
| Human and murine blood monocyte | Exosomal αvβ6 | - | CCL2/CCR2, STAT3 (M2) | CD204, CD163 (M2) | [ |
| Microglia cell line N9 | LPS (0.1 µg/mL)/IL-4 (20 ng/mL) + Anthocyanins | - | - | [ | |
| Primary microglia cells | IL-4 (10 ng/mL) + | - | - | [ | |
| Primary Kuffer cells Bone Marrow-derived macrophage (BMDM) | IL-4 | - | CD80 (M1) CD206, CD163 (M2) | [ | |
| Bone Marrow-derived macrophage (BMDM) treated mice (liver tissue) | LPS + IFNγ/IL-4 | CCL2, CCL3 (M1) Lyc6 (New classification) | - | [ | |
| CD14+ peripheral blood mononuclear cells | IFNγ (100 ng/mL)/IL-4 (10 ng/mL) + M-CSF (5 ng/mL) | - | TNF-α, IL-1β IL-1Rα, CCL18 (M1) | - | [ |
| Primary microglia cells | Erythrocyte lysates + | - | - | [ | |
| BV2 microglia cells Primary microglia cell culture | LPS (200 ng/mL) + IFNγ (20 ng/mL)/IL-4 (10 ng/mL)/ | IL-1β, TNF-α (M1) IL-10 (M2) | CD86 (M1) CD206 (M2) | [ | |
| RAW264.7 Bone Marrow-derived macrophage (BMDM) | LPS (10 ng/mL) + IFNγ (10 ng/mL)/ IL-4 (10 ng/mL) + isomeranzin | IL-1β, IL-6, TNF-α (M1) | CD11, iNOS (M1) | [ | |
| Primary microglia cells BV-2 cells | LPS (0.1-1 µg/mL) + | TNF-α, IL-6 (M1) IL-10, IL-1Rα (M2) | CD206 (M2) | [ | |
| RAW264.7 | LPS (500 ng/mL) + IFNγ (20 ng/mL) | - | - | CD86 (M1) CD206 (M2) | [ |
| Bone Marrow-derived macrophage (BMDM) | - | - | Arg-1 (M2) | CD206 (M2) | [ |
| Peripheral blood CD14+ monocyte | GM-CSF (50 ng/mL)+LPS (1 ng/mL) + IFNγ (20 ng/mL)/M-CSF (100 ng/mL) + IL-4 (20 ng/mL) + pentacyclic tirterpene Lupeol | - | CD86 (M1)CD206 (M2) | [ | |
| Mouse peritoneal macrophages | LPS (1 µg/mL) + | - | - | [ |
Arg1, Arginase 1; CCL, C-C motif chemokine ligand; CCR, C-C chemokine receptor; Chi3l3, Chil3 chitinase-like 3; COX-2, cyclooxygenase-2; CX3CR1, CX3C chemokine receptor 1; Fizz-1, resistin like alpha; GM-CSF, Granulocyte-macrophage colony-stimulating factor; IFNγ, Interferon gamma; iNOS, Inducible nitric oxide synthase; IRF, interferon regulatory factor; LPS, lipopolysaccharides; M-CSF, macrophage colony-stimulating factor; Mgl1, C-type lectin domain family 10, member A; Mrc1, Macrophage mannose receptor-1; NOS2, Nitric oxide synthase 2; PPARγ, Peroxisome proliferator-activated receptor gamma; Retnlα, Resistin-like molecule alpha; SOCS3, Suppressor of cytokine signaling 3; Tim-3, T-cell immunoglobulin and mucin-domain containing-3; TGF-β, Transforming growth factor beta; TNF-α, Tumor necrosis factor alpha; Ym1, Chitinase 3-like 3.
Inflammation inducers and samples intervened in macrophages polarization in/isolated from various tissues with gene expressed, cytokines/chemokines produced and surface markers being observed and used as indicators of polarized macrophages of different states in some recent studies. (Samples intervened were underlined to differentiate with inducers.)
| Inducers/ | Gene Expressed | Cytokines | Surface Markers | References | |
|---|---|---|---|---|---|
| Ipsilateral and contralateral hippocampi | CCl | IL-1β, IL-6, TNF-α, IFN-γ (M1) IL-4, IL-10, IL-13 (M2) | - | [ | |
| Brain tissue | Cuprizone + | IL-18 (M1)- | CD86 (M1) CD206 (M2) | [ | |
| Colonic tissue Peritoneal macrophage | DSS + | IL-1β, IL-6, TNF-α, MPO, iNOS (M1) - | - | [ | |
| Tumor region at colonic tissue | APCmin/+ mice given high fat diet + | - | - | CD206 (M2) | [ |
| Arteriosclerotic plaque | Irgm1−/− and ApoE−/− given western diet | - | iNOS (M1) Arg-1, Fizz-1 (M2) | CD16/32 (M1)- | [ |
| Adipose tissue | High fat diet + | - | IL-1β, TNF-α (M1) IL-10 (M2) | NOS2 (M1)- | [ |
| Serum, BALF and Lung tissue | LPS/ Puncture (CLP) surgery + | IL-1β, IL-6, TNF-α (M1)- | CD11c (M1)- | [ | |
| Adipose tissue | High fat diet + | TNF-α, CCL2, IL-1β, IL-6, IL-12, CCR7, MHCII (M1) IL-10, MGL1/2, Arg-1 (M2) | CD80 (M1) CD206 (M2) | [ | |
| Myocardial tissue in heart injury | EAM (treatment) + | - | - | [ | |
| Liver tissue | TAA | - | IFN-γ, TNF-α, MCP-1, Iba-1, MHC II (M1) IL-4, TGF-β, Gal-3, Hsp25 (M2) | CD68 (M1) CD163, CD204 (M2) | [ |
| Colonic tissue | TNBS + | - | CD86 (M1)- | [ | |
| Intestinal macrophages isolated from intestinal lamina propria cells | DSS + | - | CD16/32 (M1) Dectin-1 (M2) | [ | |
| Benign and malignant tumor (breast cancer) | Canine mammary tumors | - | NOS2 (M1) | -CD206 (M2) | [ |
| Blood monocyte Red pulp macrophage and monocyte in murine spleen Synovial tissue Joint lavage | Hemathrosis induction | - | MHC1, MHC2, Ly-6C (M1) | CD86 (M1) CD163 (M2) | [ |
| Microglia cells isolated from myeloid cells | Alcohol | - | MHC II, iNOS (M1) MMR (M2) | CD86 CD16/32 (M1) CD206 (M2) | [ |
| Perihematomal region of cerebral tissues | Blood injection into striatum | - | iNOS, IL-1β, TNF-α (M1) | - | [ |
| Placenta cells Splenocytes | Maternal low protein diet | TNF-α (M1) IL-6, TNF-α (M2b), CCL4 (M2) | CD274 (M1) CD163 (M2) | [ | |
| Liver tissue/serum/BALF Colonic tissue | LPS/DSS/TNBS + | IL-1β, IL-6, TNF-α (M1) | - | [ | |
| Colonic tissue | DSS + | - | IL-1β, IL-6, TNF-α, IL-10 (M1) | CD11c (M1) CD206 (M2) | [ |
| Colonic tissue | DSS + | CD86 (M1) CD206 (M2) | [ | ||
| Mouse colonic lamina propria mononuclear cells | DSS + | - | - | [ |
Arg1, Arginase 1;BALF, Bronchoalveolar lavage fluid; CCL, C-C motif chemokine ligand; CCR, C-C chemokine receptor; Chi3l3, Chil3 chitinase-like 3; COX-2, cyclooxygenase-2; CX3CR1, CX3C chemokine receptor 1; DSS, Dioctyl sodium sulfosuccinate; Fizz-1, resistin like alpha; GAL-3, Galectin-3; GM-CSF, Granulocyte-macrophage colony-stimulating factor; Iba-1, Ionized calcium-binding adapter molecule 1; IFNγ, Interferon gamma; iNOS, Inducible nitric oxide synthase; IRF, interferon regulatory factor; HSP25, Heat shock protein 25; LPS, lipopolysaccharides; Ly6c, lymphocute antigen 6 complex; M-CSF, macrophage colony-stimulating factor; MCP1, Monocyte chemoattractant protein 1; Mgl1, C-type lectin domain family 10, member A; MHCII, Major hiscompatibility complex II; Mrc1, Macrophage mannose receptor-1; MPO, Myeloperoxidase; NOS2, Nitric oxide synthase 2; PPARγ, Peroxisome proliferator-activated receptor gamma; Retnlα, Resistin-like molecule alpha; SOCS3, Suppressor of cytokine signaling 3; TAA, Thioacetamide; Tim-3, T-cell immunoglobulin and mucin-domain containing-3; TGF-β, Transforming growth factor beta; TNBS, 2, 4, 6-Trinitrobenzenesulfonic acid solution; TNF-α, Tumor necrosis factor alpha; Tream2, Triggering receptor expressed on myeloid cells 2; Ym1, Chitinase 3-like 3.
Figure 1M1 macrophage polarization mechanisms mentioned in Section 2. Blue circle, inducers; white blocks, genes/proteins involved.
Figure 2M2 macrophage polarization mechanisms mentioned in Section 2. Blue circle, inducers; white blocks, genes/proteins involved.
Figure 3Some strategies proposed for intestinal and colorectal diseases amelioration mentioned in Section 3. Blue circle, samples intervened; yellow block, microRNA intervened; white blocks, genes/proteins involved.
Figure 4Some strategies proposed for brain injuries attenuation and neuron protection mentioned in Section 5. Blue circle, samples intervened; yellow block, microRNA intervened; white blocks, genes/proteins involved.